Strategic partnerships Nanexa actively partners with major pharma companies for PharmaShell, including recent collaborations with Moderna and Novo Nordisk, signaling opportunities to position complementary drug delivery capabilities to large pharmas pursuing long-acting or mRNA-based therapies.

mRNA collaboration Significant recent and upcoming deals with Moderna for PharmaShell in mRNA therapeutics suggest a strong market signal for creating sales pitches around mRNA delivery optimization, rapid scaling potential, and ALD-based stability enhancements.

Long‑acting injections The joint development with Novo Nordisk on long-acting injectable treatments in cardiometabolic indications highlights a target area where PharmaShell can address duration, adherence, and dosing advantages for life‑cycle management and affordability.

Scale and manufacturing Plans to develop GMP‑compliant ALD manufacturing equipment with Forge Nano indicate a capability upgrade for clinical and potential commercial scale, offering sales angles around manufacturing readiness, quality, and supply continuity.

Funding momentum Recent warrant exercises and ongoing high‑value license agreements reflect healthy funding and growth trajectory, creating opportunities to engage as a strategic supplier of early‑stage to clinical‑stage delivery solutions during funding rounds and program milestones.